Biotech Values

[rfj1862]

<Among the challenges confronting companies like Roche seeking to sell the new gene therapies is gaining reimbursement. Spark has said it plans to sell Luxturna in the U.S. at a cost of $850,000 a patient."

Are they totally insane

?

I don't know the economics of this treatment, but I do know that the gene therapies for hemophilia are going to be priced at >$1M. Given that some of these patients can consume antihemophilic factors at a rate of $500K to $1M a year, the treatment is a bargain. I suspect that a blind person also incurs considerable societal costs that are far more than $850K over a lifetime in western countries.